Clinical trials: Cardiac Rhythm Disorders
Persistent Atrial Fibrillation
Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion
Dose-ranging Phase II study testing the efficacy and safety of 3 doses of Ranolazine (low, intermediate and high, given BID) versus placebo in maintaining sinus rhythm after successful electrical cardioversion in patients with…
- Trial name
- RAFFAELLO (NCT01534962)
- Testing
- Ranolazine
- Where
- 4 sites in Germany, Italy and 2 more
- Volunteers
- 241 people
- Sponsor
- Menarini Group
Atrial Fibrillation
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Atrial fibrillation (AF) is the most common sustained abnormal rhythm of the heart, affects an estimated 2.5 to 5 million individuals in the US, and can lead to stroke, heart failure, and premature death.
- Trial name
- REACT COM (NCT01706146)
- Testing
- Non-coumadin Oral Anticoagulant
- Where
- 3 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Northwestern University
Atrial Fibrillation
A Fib Clinic of the Future Using KardiaPro Platform for Chronic Care of Patients With AF After Ablation Procedure
Pulmonary vein isolation is a widely used strategy for the treatment of patients with symptomatic atrial fibrillation. After successful pulmonary vein isolation (no atrial fibrillation on transtelephonic rhythm recordings for 3…
- Trial name
- AliveCor (NCT03557034)
- Testing
- Kardia Monitoring
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- The Cleveland Clinic
Fibrillation, Atrial
Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm
The purpose of this study is to test whether Fondaparinux is effective and safe to prevent thromboembolic events (like for example strokes) and bleeding events in patients who undergo a normalisation of their heart rhythm…
- Trial name
- NCT00911300
- Testing
- fondaparinux, unfractionated heparin, Vitamin-K-Antagonist
- Where
- 34 sites in France, Germany
- Volunteers
- 349 people
- Sponsor
- GlaxoSmithKline
Heart Rate and Rhythm Disorders
Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter
Acute atrial fibrillation is the most common sustained, clinically significant dysrhythmia encountered in the emergency department (ED) and the most common dysrhythmia treated by emergency physicians.
- Trial name
- DiME (NCT01914926)
- Testing
- Metoprolol, Diltiazem
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Antonios Likourezos
Heart Failure, Atrial Fibrillation
Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio-ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation
Atrial fibrillation and heart failure are two common heart conditions that are associated with an increase in death and suffering. When both of these two conditions occur in a patient the patient's prognosis is poor.
- Trial name
- RAFT-AF (NCT01420393)
- Testing
- Rhythm control, Rate Control
- Where
- 21 sites in Brazil, Canada and 2 more
- Volunteers
- 411 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Heart Arrest, Cardiac Arrest
Impact of Speed Of Rewarming After CaRdiac Arrest and ThErapeutic Hypothermia
Comparing the production of interleukin 6 (inflammatory cytokine) in two heating speed (slow rewarming rate: 0.25 ° C / h or fast rewarming rate 0.50 ° C / h) at the completion of a period of targeted temperature at 33°C after…
- Conditions
- Heart Arrest, Cardiac Arrest, Hypothermia
- Trial name
- ISOCRATE (NCT02555254)
- Testing
- Low Speed of Rewarming, High Speed of Rewarming
- Where
- France
- Volunteers
- 58 people
- Sponsor
- Centre Hospitalier Departemental Vendee
Hypoglycemia, Type 2 Diabetes
Hypoglycemia (Low Blood Sugar) and the Heart
The risk of hypoglycemia (low blood sugar) associated with the treatment of diabetes increases with age. Hypoglycemia is a common reason for admission to hospital for older patients with diabetes.
- Trial name
- NCT01980914
- Testing
- iPro2 glucose sensor attachment
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University of British Columbia
Atrial Fibrillation, Atrial Flutter
iPhone Helping Evaluate Atrial Fibrillation Rhythm Through Technology
Atrial fibrillation (AF), a condition where the top chambers of the heart beat irregularly, is a major health problem. The long-term goal of this project is to use a personal, mobile heart monitor to help patients better…
- Trial name
- iHEART (NCT02731326)
- Testing
- AliveCor, Behavioral Altering Messaging
- Where
- United States
- Volunteers
- 264 people
- Sponsor
- Columbia University
Cardiac Rhythm Disorder, Bradycardia
The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System
prospective, non-randomized, multi-center, international clinical study is designed to confirm the safety and effectiveness of the Aveir LP System in a subject population indicated for a VVI(R) pacemaker.
- Trial name
- NCT04559945
- Testing
- Aveir VR Leadless Pacemaker System
- Where
- 53 sites in United States, Canada and 6 more
- Volunteers
- 1,276 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation
This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke
This is an observational study in patients with non-valvular atrial fibrillation (NVAF) presenting to the hospital with a first acute ischemic stroke based on existing data recorded in the SITS International Registry (located in…
- Trial name
- NCT03258645
- Testing
- Dabigatran
- Where
- Sweden
- Volunteers
- 1,489 people
- Sponsor
- Boehringer Ingelheim
Stroke, Atrial Fibrillation
Post-Embolic Rhythm Detection With Implantable Versus External Monitoring
The overall aim of this trial is to determine the most cost effective approach to diagnose paroxysmal atrial fibrillation (PAF) following transient ischemic attack (TIA) and stroke.
- Conditions
- Stroke, Atrial Fibrillation, Arrhythmias, Cardiac
- Trial name
- PERDIEM (NCT02428140)
- Testing
- Medtronic Reveal LINQ, Sorin Spiderflash-t
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- University of Alberta
Heart Diseases, Rhythm; Abnormal
BIO|CONCEPT.ECG-Library (Collection of ECG Signals for Development of Algorithms)
Collection of Holter surface ECGs for the development of new sensing and detection algorithms
- Trial name
- NCT04243070
- Testing
- 3-channel Holter ECG recording, 12-channel Holter ECG recording
- Where
- 5 sites in Germany
- Volunteers
- 89 people
- Sponsor
- Biotronik SE & Co. KG
Atrial Fibrillation
Prediction and Maintenance of Sinus Rhythm Among Atrial Fibrillation Patients
Atrial fibrillation (AF) is the most common heart rhythm disorder seen in clinical practice, with an estimated 2.7-6.1 million people in the U.S. affected by the disorder [1].
- Trial name
- NCT04313296
- Testing
- Unique measurement (AutoSTRAIN) by a commercial software program (TOMTEC-ARENA)
- Where
- United States
- Volunteers
- 209 people
- Sponsor
- Crystal Blake-Parlin
Paroxysmal Supraventricular Tachycardia (PSVT)
Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm
The primary objective of this study is to demonstrate the superiority of at least 1 dose of intranasal (IN) MSP-2017 (Etripamil) over placebo in terminating PSVT induced in an electrophysiology (EP) laboratory.
- Trial name
- NODE-1 (NCT02296190)
- Testing
- Etripamil
- Where
- 30 sites in United States, Canada
- Volunteers
- 199 people
- Sponsor
- Milestone Pharmaceuticals Inc.
Atrial Fibrillation
Efficacy and Safety Study of F373280
The purpose of this study is to assess the efficacy of F373280 on the maintenance of normal cardiac rhythm after direct electric cardioversion in patients with persistent atrial fibrillation and cardiac failure.
- Trial name
- NCT01831856
- Testing
- 1g of F373280
- Where
- 20 sites in Czechia, Hungary and 3 more
- Volunteers
- 135 people
- Sponsor
- Pierre Fabre Medicament
Tachycardia
RIGHT: Rhythm ID Going Head-to-Head Trial
RIGHT is a randomized, prospective, two-arm study that will assess the differential efficacy of VITALITY 2 implantable cardioverter defibrillators (ICDs) using Rhythm ID™ versus selected Medtronic ICDs.
- Trial name
- NCT00148954
- Testing
- VITALITY 2 Implantable Cardioverter Defibrillator, Medtronic Implantable Cardioverter Defibrillator
- Where
- United States
- Volunteers
- 1,962 people
- Sponsor
- Boston Scientific Corporation
Heart Failure
Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM)
The purpose of this study was to generate effectiveness data of Angiotensin receptor neprilysin inhibitor (ARNI), in the Chinese Heart failure with reduced ejection fraction (HFrEF) patients with implantable cardioverted…
- Trial name
- RHYTHM (NCT04491136)
- Testing
- ACEI/ARB, ARNI
- Where
- 23 sites in China
- Volunteers
- 201 people
- Sponsor
- Novartis Pharmaceuticals